Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study
Use este enlace para citar
http://hdl.handle.net/2183/37625
A non ser que se indique outra cousa, a licenza do ítem descríbese como Atribución-NoComercial-SinDerivadas 3.0 España
Coleccións
- II - Artigos [544]
Metadatos
Mostrar o rexistro completo do ítemTítulo
Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI StudyAutor(es)
Data
2018-10Cita bibliográfica
Diego Bellido, Pablo Abellán, José Manuel Ruiz Palomar, Rogelio Álvarez Sintes, Andreu Nubiolae, Virginia Bellido, Gracia Romero, Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study, Current Therapeutic Research, Volume 89, 2018, Pages 37-42, ISSN 0011-393X, https://doi.org/10.1016/j.curtheres.2018.09.001.
Resumo
[Abstract] Background: Basal insulin reduces fasting blood glucose levels, but postprandial blood glucose levels may
remain higher. Traditional strategies with rapid insulin intensification can cause hypoglycemic episodes
and weight gain. Glucagon-like peptide-1 receptor agonists, such as the short-acting lixisenatide, are able
to control postprandial excursions, without weight gain, and with a low risk of hypoglycemic events.
Objective: Due to the limited data on the combination of lixisenatide with basal insulin (with or without
oral antidiabetes drugs) in clinical practice, this study evaluated changes in parameters associated with
glycemic control and anthropometric data after 24 weeks of this therapy intensification.
Methods: This was a multicenter, retrospective observational study of 129 patients with type 2 diabetes
that was uncontrolled by basal insulin. Their treatment was intensified by the addition of lixisenatide
at least 24 weeks before being included in the study. Data were retrospectively collected to determine
changes in glycated hemoglobin (HbA1c) levels, blood glucose levels, weight, and body mass index. Adverse
reactions and hypoglycemic events were also recorded.
Results: After 24 weeks of therapy intensification with lixisenatide, a significant reduction in HbA1c levels
was observed (–1.1%; P < 0.001). An HbA1c < 7% was achieved in 30.2% of patients, and 17.1% reached
an HbA1c < 6.5%. There was a reduction in fasting blood glucose (31.8 [60.3] mg/dL; P < 0.001) and
postprandial blood glucose (55.0 [49] mg/dL; P < 0.001) levels, as well as body weight (4.0 [5.4] kg; P <
0.001) and body mass index (1.5 [1.9]; P < 0.001). The most commonly observed adverse reactions were
nausea (n = 9), in line with previous studies. Hypoglycemia events were rare; only reported in 2 patients.
Conclusions: Intensification strategy based on lixisenatide added to basal insulin (with or without oral
antidiabetes drugs) can be an effective treatment option in patients with uncontrolled type 2 diabetes.
In this small, selected population, glycemic control was significantly improved in terms of HbA1, fasting
blood glucose levels, and postprandial glucose levels, with a reduction of body weight and low risk of
hypoglycemic events.
Palabras chave
basal insulin
GLP-1 RA
hypoglycemia
intensification therapy
lixisenatide
type 2 diabetes
GLP-1 RA
hypoglycemia
intensification therapy
lixisenatide
type 2 diabetes
Versión do editor
Dereitos
Atribución-NoComercial-SinDerivadas 3.0 España